Sertoli-Leydig cell tumor characterized by hyperestrogenism in a postmenopausal woman: a case report and review of the literature

Sertoli-Leydig cell tumor (SLCT) is a rare neoplasm from the group of sex-stromal tumors of ovary, which accounts for < 0.5% of all primary ovarian tumors. The tumor can occur in all ages but is more often seen in young women at the mean age of 25 years. Less than 10% of the SLCTs occur before menarche or after menopause. Although most SLCTs have a good prognosis if detected in Stage I, but the most common are those with moderate or poor differentiation. In order to monitor the risk of disease recurrence, close followup is required. In this article the rare case of SLCT in a 62-year-old woman characterized by postmenopausal bleeding and hyperestrogenism was reported, The clinical and pathological characteristics were described. Clinicians should consider that patients with postmenopausal bleeding and hyperestrogenism should be highly suspicious of SLCT, and more prospective studies on the diagnosis and the course of the diseases are needed.

Sertoli-Leydig cell tumor; Hyperestrogenism; Postmenopausal bleeding.

[1] Young R.H., Scully R.E.: “Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases”. Am. J. Surg. Pathol., 1985, 9, 543.

[2] Kawatra V., Mandal S., Khurana N., Aggarwal S.K.: “Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl”. J. Obstet. Gynaecol. Res., 2009, 35, 176.

[3] Talerman A.: “Ovarian Sertoli-Leydig cell tumor (androblastoma) with retiform pattern. A clinicopathologic study”. Cancer, 1987, 60, 3056.

[4] Chen L., Tunnell C.D., De Petris G.: “Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature”. Int. J. Clin. Exp. Pathol., 2014, 7, 1176.

[5] Mooney E.E., Nogales F.F., Bergeron C., Tavassoli F.A.: “Retiform Sertoli-Leydig cell tumours: clinical morphological and immunohistochemical findings”. Histopathology, 2002, 41: 110-117.

[6] Bhat R.A., Lim Y.K., Chia Y.N., Yam K.L.: “Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database”. J. Obstet. Gynaecol. Res., 2013, 39, 305.

[7] Young R.H., Prat J., Scully R.E.: “Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases”. Cancer, 1982, 50, 2448.

[8] Riopel M.A., Perlman E.J., Seidman J.D., Kurman R.J., Sherman M.E., et al.: “Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas”. Int. J. Gynecol. Pathol., 1998, 17, 46.

[9] Zhao C., Bratthauer G.L., Barner R., Vang R.: “Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases”. Am. J. Surg. Pathol., 2007, 31, 255-266.

[10] Abu-Zaid A., Azzam A., Alghuneim L.A., Metawee M.T., Amin T., Al-Hussain T.O., et al.: “Poorly differentiated ovarian sertoli-leydig cell tumor in a 16-year-old single woman: a case report and literature review”. Case Rep. Obstet. Gynecol., 2013, 2013, 858501.

[11] Tayade S., Shivkumar P.V.: “Malignant Sertoli Ledig Cell Tumor of Ovary in a Young Adolescent”. IJBR, 2012, 3, 226.

[12] Manjeera L., Rai S.: “A case of ovarian Sertoli-Leydig cell tumor with multiple endocrine gland involvement”. Int. J. Reprod., 2012, 1, 55-57.

[13] Rosai J., Ackeaman G.: “Surgical Pathology”. 10th ed. New York: Elsevier Mosby, 2012.

[14] Tandon R., Goel P., Saha P.K., Takkar N., Punia R.P.: “A rare ovarian tumor - SertoliLeydig cell tumor with heterologous element”. Med. Gen. Med.,2007, 9, 44.

[1]5 Desai V.R., Dave K.S., Mankad M.H., Dave P.S., Bhansali R.P., Desai A.D.: “Sertoli leydig cell tumors of ovary”. J. Obstet. Gynecol. India, 2009, 59, 165.

[16] Gui T., Cao D., Shen K, Yang J., Zhang Y., Yu Q., et al.: “A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors”. Gynecol. Oncol., 2012, 127, 384.

[17] Fleckenstein G., Sattler B., Hinney B., Wuttke W., Osmers R., Emons G, et al.: “Androblastoma of the ovary: clinical diagnostic and histopathologic features”. Oncology, 2001, 24, 286.

[18] Sigismondi C., Gadducci A., Lorusso D., Candiani M., Breda E., Raspagliesi F., et al.: “Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study”. Gynecol. Oncol., 2012, 125, 673.

[19] Morgan R.J. Jr., Alvarez R.D., Armstrong D.K., Burger R.A., Chen L.M., Copeland L., et al.: “Ovarian cancer, version 2.2013”. J. Natl. Compr. Canc. Netw., 2013, 11, 1199.

[20] Brown J., Sood A.K., Deavers M.T., Milojevic L., Gershenson D.M.: “Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?” Gynecol. Oncol., 2009, 113, 86.